Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Reviews Disease Primers. 2021;7(1):3.

Article  PubMed  Google Scholar 

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell Lung Cancer. N Engl J Med. 2018;379(23):2220–9.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet (London England). 2019;394(10212):1929–39.

Article  CAS  PubMed  Google Scholar 

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–47.

Article  CAS  PubMed  Google Scholar 

Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, et al. Effect of First-Line Serplulimab vs Placebo added to Chemotherapy on Survival in patients with extensive-stage small cell Lung Cancer: the ASTRUM-005 Randomized Clinical Trial. JAMA. 2022;328(12):1223–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Y, Zheng Y, Wang PP, Ding ZY. Toxicities of Immunotherapy for Small Cell Lung Cancer. Front Oncol. 2021;11:603658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. Safety Profile of Nivolumab Monotherapy: a pooled analysis of patients with Advanced Melanoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35(7):785–92.

Article  CAS  Google Scholar 

Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: characteristics of Immune-Related Adverse Events and Association with outcomes. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(4):886–94.

Article  CAS  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer. J Natl Compr Cancer Network: JNCCN. 2013;11(1):99–104.

Article  Google Scholar 

Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, et al. Multisystem Immune-related adverse events Associated with Immune Checkpoint inhibitors for treatment of Non-small Cell Lung Cancer. JAMA Oncol. 2020;6(12):1952–6.

Article  PubMed  Google Scholar 

Shimozaki K, Sukawa Y, Beppu N, Kurihara I, Suzuki S, Mizuno R, Funakoshi T, Ikemura S, Tsugaru K, Togasaki K, et al. Multiple Immune-related adverse events and Anti-tumor Efficacy: real-World Data on various solid tumors. Cancer Manage Res. 2020;12:4585–93.

Article  CAS  Google Scholar 

Qin S, Li J, Zhong H, Jin C, Chen L, Yuan X, Fan Q, Chen K, Cao P, Xiao J, et al. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. Br J Cancer. 2022;127(12):2241–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun C, Zhang L, Zhang W, Liu Y, Chen B, Zhao S, Li W, Wang L, Ye L, Jia K, et al. Expression of PD-1 and PD-L1 on Tumor-infiltrating lymphocytes predicts prognosis in patients with small-cell Lung Cancer. OncoTargets Therapy. 2020;13:6475–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, Millward M, Gray ES. Tumour PD-L1 expression in small-cell lung Cancer: a systematic review and Meta-analysis. Cells 2020, 9(11).

Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019;7(1):87.

Article  PubMed  PubMed Central  Google Scholar 

Keogh A, Finn S, Radonic T. Emerging biomarkers and the changing Landscape of Small Cell Lung Cancer. Cancers 2022, 14(15).

Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell Lung Cancer receiving baseline corticosteroids for Palliative Versus Nonpalliative indications. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(22):1927–34.

Article  CAS  Google Scholar 

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, et al. Outcome of patients with Non-small Cell Lung Cancer and Brain metastases treated with checkpoint inhibitors. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14(7):1244–54.

Article  CAS  Google Scholar 

Scott SC, Pennell NA. Early Use of systemic corticosteroids in patients with Advanced NSCLC treated with Nivolumab. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2018;13(11):1771–5.

Article  Google Scholar 

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, et al. Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell Lung Cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36(28):2872–8.

Article  CAS  Google Scholar 

Shafqat H, Gourdin T, Sion A. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol. 2018;45(3):156–63.

Article  CAS  PubMed  Google Scholar 

Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: assessing Chronic Immune Toxicities, Health outcomes, and functional status among long-term Ipilimumab survivors at a single Referral Center. Cancer Immunol Res. 2015;3(5):464–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D’Angelo SP, Woo KM, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on Survival and Time to Treatment failure in patients with melanoma treated with Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(28):3193–8.

Article  CAS  Google Scholar